Theravance Biopharma Inc (TBPH)
9.61
-0.36
(-3.61%)
USD |
NASDAQ |
Nov 21, 16:00
9.62
+0.01
(+0.10%)
Pre-Market: 20:00
Theravance Biopharma Enterprise Value: 381.20M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 381.20M |
| November 20, 2024 | 398.91M |
| November 19, 2024 | 396.45M |
| November 18, 2024 | 375.30M |
| November 15, 2024 | 376.78M |
| November 14, 2024 | 379.24M |
| November 13, 2024 | 384.65M |
| November 12, 2024 | 346.78M |
| November 11, 2024 | 355.14M |
| November 08, 2024 | 348.26M |
| November 07, 2024 | 338.91M |
| November 06, 2024 | 336.94M |
| November 05, 2024 | 315.31M |
| November 04, 2024 | 312.36M |
| November 01, 2024 | 315.80M |
| October 31, 2024 | 313.83M |
| October 30, 2024 | 325.14M |
| October 29, 2024 | 333.99M |
| October 28, 2024 | 339.90M |
| October 25, 2024 | 329.08M |
| October 24, 2024 | 333.50M |
| October 23, 2024 | 333.01M |
| October 22, 2024 | 341.37M |
| October 21, 2024 | 334.49M |
| October 18, 2024 | 341.37M |
| Date | Value |
|---|---|
| October 17, 2024 | 332.52M |
| October 16, 2024 | 336.45M |
| October 15, 2024 | 331.54M |
| October 14, 2024 | 313.34M |
| October 11, 2024 | 317.27M |
| October 10, 2024 | 304.98M |
| October 09, 2024 | 304.98M |
| October 08, 2024 | 298.59M |
| October 07, 2024 | 304.49M |
| October 04, 2024 | 306.95M |
| October 03, 2024 | 306.95M |
| October 02, 2024 | 312.36M |
| October 01, 2024 | 312.36M |
| September 30, 2024 | 304.98M |
| September 27, 2024 | 300.19M |
| September 26, 2024 | 298.23M |
| September 25, 2024 | 293.34M |
| September 24, 2024 | 296.28M |
| September 23, 2024 | 292.36M |
| September 20, 2024 | 295.79M |
| September 19, 2024 | 305.57M |
| September 18, 2024 | 308.51M |
| September 17, 2024 | 307.04M |
| September 16, 2024 | 301.17M |
| September 13, 2024 | 302.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
163.25M
Minimum
Nov 02 2022
2.047B
Maximum
Apr 29 2020
926.91M
Average
1.108B
Median
Feb 07 2022
Enterprise Value Benchmarks
| Corcept Therapeutics Inc | 5.479B |
| Madrigal Pharmaceuticals Inc | 6.299B |
| Ionis Pharmaceuticals Inc | 4.154B |
| Jazz Pharmaceuticals PLC | 11.06B |
| NovaBay Pharmaceuticals Inc | 2.798M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.70M |
| Revenue (Quarterly) | 16.87M |
| Total Expenses (Quarterly) | 26.14M |
| EPS Diluted (Quarterly) | -0.26 |
| Profit Margin (Quarterly) | -75.28% |
| Earnings Yield | -10.51% |
| Normalized Earnings Yield | -9.750 |